Andrew M. Intlekofer performed his undergraduate studies at the University of Maryland Baltimore County, graduating summa cum laude in 2001 with a B.S. in Biochemistry. He then received his M.D. and Ph.D. in Immunology from the University of Pennsylvania School of Medicine. At Penn under the mentorship of Dr. Steven Reiner, Dr. Intlekofer made seminal discoveries concerning the mechanistic basis of effector and memory T cell differentiation, which were recognized by the Saul Winegrad Award for Outstanding Ph.D. Dissertation. He subsequently trained in Internal Medicine at the New York Presbyterian/Weill Cornell Medical Center and in Medical Oncology at Memorial Sloan Kettering Cancer Center (MSK). As a postdoctoral researcher under the mentorship of Craig Thompson, Dr. Intlekofer made groundbreaking discoveries elucidating how hypoxia-induced metabolism controls epigenetics and differentiation in normal and malignant cells. In the Fall of 2017, Dr. Intlekofer established his independent laboratory in the Human Oncology & Pathogenesis Program (HOPP) at MSK, while continuing patient care with Lymphoma Service in the Department of Medicine. This Intlekofer lab investigates how metabolites function as physiologic signals and how deregulated cellular metabolism contributes to cancer development. Dr. Intlekofer’s group has made critical discoveries that directly impact patient care, including identification of the first mechanisms of acquired resistance to targeted metabolic therapies. Their more recent mechanistic dissections of drug resistance mutations in isocitrate dehydrogenase will establish an exciting new paradigm for hyperactivation (rather than inhibition) of metabolic enzymes for cancer therapy. Dr. Intlekofer’s research has been supported by the NIH/NCI, Burroughs Wellcome Fund, Damon Runyon Cancer Research Foundation, Leukemia & Lymphoma Society, Cycle for Survival, Geoffrey Beene Foundation, Starr Cancer Consortium, and Gabrielle’s Angel Foundation.